INTRODUCTION: In this study, we assessed the whole-body biodistribution and radiation dosimetry of the new glutamatergic ligand (11)C-ABP688. This ligand binds specifically to the metabotropic glutamatergic receptor of subtype 5 (mGluR5). MATERIALS AND METHODS: The study included five healthy male volunteers aged 20-29 years. After intravenous injection of 240-260 MBq, a series of four to ten whole-body positron emission tomography/computed tomography scans were initiated, yielding 60-80 min of data. Residence times were then calculated in the relevant organs, and the software packages Mirdose and Olinda were used to calculate the absorbed radiation dose and the effective dose equivalent. RESULTS: Of the excreted (11)C activity at 1 hour, approximately 80% were eliminated via the hepato-biliary pathway and 20% through the urinary tract. The absorbed dose (mGy/MBq) was highest in the liver (1.64 E (-2) +/- 5.08 E (-3)), gallbladder (8.13 E (-3) +/- 5.6 E (-3)), and kidneys (7.27 E (-3) +/- 2.79 E (-3)). The effective dose equivalent was 3.68 +/- 0.84 microSv/MBq. Brain uptake in the areas with high mGluR5 density was 2-3 (SUV). The agreement between the values obtained from Mirdose and the Olinda was excellent. CONCLUSION: (11)C-ABP688 is a very promising ligand for the investigation of mGluR5 receptors in humans. Brain uptake is high and the effective dose equivalent so low that serial examinations in the same subject seem feasible.
INTRODUCTION: In this study, we assessed the whole-body biodistribution and radiation dosimetry of the new glutamatergic ligand (11)C-ABP688. This ligand binds specifically to the metabotropic glutamatergic receptor of subtype 5 (mGluR5). MATERIALS AND METHODS: The study included five healthy male volunteers aged 20-29 years. After intravenous injection of 240-260 MBq, a series of four to ten whole-body positron emission tomography/computed tomography scans were initiated, yielding 60-80 min of data. Residence times were then calculated in the relevant organs, and the software packages Mirdose and Olinda were used to calculate the absorbed radiation dose and the effective dose equivalent. RESULTS: Of the excreted (11)C activity at 1 hour, approximately 80% were eliminated via the hepato-biliary pathway and 20% through the urinary tract. The absorbed dose (mGy/MBq) was highest in the liver (1.64 E (-2) +/- 5.08 E (-3)), gallbladder (8.13 E (-3) +/- 5.6 E (-3)), and kidneys (7.27 E (-3) +/- 2.79 E (-3)). The effective dose equivalent was 3.68 +/- 0.84 microSv/MBq. Brain uptake in the areas with high mGluR5 density was 2-3 (SUV). The agreement between the values obtained from Mirdose and the Olinda was excellent. CONCLUSION: (11)C-ABP688 is a very promising ligand for the investigation of mGluR5 receptors in humans. Brain uptake is high and the effective dose equivalent so low that serial examinations in the same subject seem feasible.
Authors: F Gasparini; K Lingenhöhl; N Stoehr; P J Flor; M Heinrich; I Vranesic; M Biollaz; H Allgeier; R Heckendorn; S Urwyler; M A Varney; E C Johnson; S D Hess; S P Rao; A I Sacaan; E M Santori; G Veliçelebi; R Kuhn Journal: Neuropharmacology Date: 1999-10 Impact factor: 5.250
Authors: Terence G Hamill; Stephen Krause; Christine Ryan; Celine Bonnefous; Steve Govek; T Jon Seiders; Nicholas D P Cosford; Jeffrey Roppe; Ted Kamenecka; Shil Patel; Raymond E Gibson; Sandra Sanabria; Kerry Riffel; Waisi Eng; Christopher King; Xiaoqing Yang; Mitchell D Green; Stacey S O'Malley; Richard Hargreaves; H Donald Burns Journal: Synapse Date: 2005-06-15 Impact factor: 2.562
Authors: E Tatarczyńska; A Klodzińska; E Chojnacka-Wójcik; A Palucha; F Gasparini; R Kuhn; A Pilc Journal: Br J Pharmacol Date: 2001-04 Impact factor: 8.739
Authors: Simon M Ametamey; Lea J Kessler; Michael Honer; Matthias T Wyss; Alfred Buck; Samuel Hintermann; Yves P Auberson; Fabrizio Gasparini; Pius A Schubiger Journal: J Nucl Med Date: 2006-04 Impact factor: 10.057
Authors: Simon M Ametamey; Valerie Treyer; Johannes Streffer; Matthias T Wyss; Mark Schmidt; Milen Blagoev; Samuel Hintermann; Yves Auberson; Fabrizio Gasparini; Uta C Fischer; Alfred Buck Journal: J Nucl Med Date: 2007-02 Impact factor: 10.057
Authors: Elyza Kelly; Samantha M Schaeffer; Sameer C Dhamne; Jonathan O Lipton; Lothar Lindemann; Michael Honer; Georg Jaeschke; Chloe E Super; Stephen Ht Lammers; Meera E Modi; Jill L Silverman; John R Dreier; David J Kwiatkowski; Alexander Rotenberg; Mustafa Sahin Journal: Neuropsychopharmacology Date: 2017-12-05 Impact factor: 7.853
Authors: William B Mathews; Hiroto Kuwabara; Kirstie Stansfield; Heather Valentine; Mohab Alexander; Anil Kumar; John Hilton; Robert F Dannals; Dean F Wong; Fabrizio Gasparini Journal: Synapse Date: 2014-08-19 Impact factor: 2.562
Authors: Jussi Hirvonen; Anne Roivainen; Jere Virta; Semi Helin; Kjell Någren; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-28 Impact factor: 9.236
Authors: Amira K Brown; Yasuyuki Kimura; Sami S Zoghbi; Fabrice G Siméon; Jeih-San Liow; William C Kreisl; Andrew Taku; Masahiro Fujita; Victor W Pike; Robert B Innis Journal: J Nucl Med Date: 2008-12 Impact factor: 10.057
Authors: Tuula Tolvanen; Timo Yli-Kerttula; Tiina Ujula; Anu Autio; Pertti Lehikoinen; Heikki Minn; Anne Roivainen Journal: Eur J Nucl Med Mol Imaging Date: 2010-01-13 Impact factor: 9.236